Sarepta Therapeutics (NASDAQ:SRPT) Issues Earnings Results

Sarepta Therapeutics (NASDAQ:SRPT) posted its earnings results on Wednesday. The biotechnology company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84, RTT News reports. The business had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.44) EPS.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded up $3.03 during midday trading on Friday, reaching $133.66. 1,196,284 shares of the company’s stock traded hands, compared to its average volume of 876,130. The company has a market cap of $12.63 billion, a price-to-earnings ratio of 1,215.09 and a beta of 0.95. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.45 and a current ratio of 4.05. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $159.89. The stock has a 50 day moving average of $125.63 and a 200 day moving average of $110.81.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SRPT. BMO Capital Markets began coverage on Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price target for the company. Citigroup lifted their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Needham & Company LLC reiterated a “buy” rating and set a $166.00 price target on shares of Sarepta Therapeutics in a research report on Thursday. Wedbush reiterated an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, TheStreet upgraded Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $160.60.

Insider Activity

In other news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at $5,018,326.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Stephen Mayo sold 3,135 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total transaction of $385,479.60. Following the transaction, the director now directly owns 6,621 shares of the company’s stock, valued at $814,118.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock valued at $2,739,419 over the last ninety days. 7.40% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.